Protocol Ledger

NCT05566990 · Phase III · COMPLETED

A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj.10% in Primary Immune Thrombocytopenia (ITP)

Interventional Phase III clinical trial protocol NCT05566990 sponsored by SK Plasma Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-07-19 Enrollment: 34 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05566990
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)34 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05566990
Protocol FieldVerified Registry Value
NCT IdentifierNCT05566990
Consolidated Lead SponsorSK Plasma Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment34 participants (ACTUAL)
Registered Start Date2019-07-19
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05566990
Hospital Research SiteLocationSite Profile
Dong-A University HospitalBusan, South KoreaOpen Hospital Dossier ->
Pusan National University HospitalBusan, South KoreaOpen Hospital Dossier ->
Kyungpook National University HospitalDaegu, South KoreaOpen Hospital Dossier ->
Chungnam National University HospitalDaejeon, South KoreaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI